Users online: 1628    [ij] [ij] [ij] 
Email id

Research Journal of Pharmacy and Technology
Year : 2018, Volume : 11, Issue : 6
First page : ( 2365) Last page : ( 2371)
Print ISSN : 0974-3618. Online ISSN : 0974-360X.
Article DOI : 10.5958/0974-360X.2018.00439.0

Comparative study between paired primary and relapsed breast cancer patients based on clinicopathological features and molecular subtypes of breast cancer in Babylon Province

Al-Shalah Mohend A. N.1,*, Al-Mosawi Hadi M.2, Alaawad Alaa Sadeq3

1MRCS-FRCS, Dept. of Surgery, College of Medicine, University of Babylon, Hilla, Iraq

2F.I.C.M.S Pathology, Clinical Pathology, Dept, College of Medicine, University of Babylon, Hilla, Iraq

3C.A.B.S, Consultant Physician, Dept. of Medicine, College of Medicine University of Babylon, Hilla, Iraq

*Corresponding Author E-mail:

Online published on 24 August, 2018.


Immunohistochemistry is routinely used to direct therapy of primary breast cancer. Biopsy from the relapsed tumor is controversy. No study in Iraqfocused on the molecular subtypes of breast cancer in loco-regional recurrence or distant metastases and correlate between these subtypes with the clinicopathological features. Paired Primary and Relapsed Breast Cancer patientswere included in this study in which 54 women with recurrent breast cancer which presented with loco-regional recurrence or distant metastases. Tissue sampling were taken from the site of recurrence either through excisional biopsy or true cut biopsy. Immunohistochemical staining were carried out for the assessment of ER, PR and (HER2) status. Retrospective dataof the primary breast cancer were collected from medical records in the oncology unit in Almerjanhospital. The primary outcomewere detection of molecular subtypes expression in both primary and relapsed breast cancer. Secondary outcome were studying the association between of these molecular subtypes of patients with recurrent breast cancer with age, duration of recurrence, stage of disease, grade of disease, type of surgery and site of metastasis and histopathological diagnosis, type of treatment including (chemotherapy, radiotherapy, hormonal therapy and monoclonal antibodies). Results show that 54 patients were diagnosed with breast cancer and treated in the tertiary breast cancer center in Alhilla general teaching hospital and followed in the oncology center in Almerjan medical teaching hospital in Alhilla, Babylon, Iraq between 2014 and 2017. The overall mean age of all patients with Recurrent Breast Cancer was(49.94±9.96). The mean Interval time for recurrence was (20.68±8.29) months. Majority (77.8%) ofpatients diagnosed as Invasive ductal carcinoma. Mastectomy plus Axillary clearance were done for 77.8% of the total patients and Breast Conserving Surgery plus Axillary clearance were done for the remainder. Site of metastasis were Local recurrence in 46.2%, Lymph node metastasis in 29.6%, Liver metastasis 13.0%, Lung metastasis 5.6% and Bone metastasis 5.6%. ImmunoHistochemical results of the studied group were either Luminal A (37%) or Luminal B (48.1%) at time of primary diagnosis while majority (75.9%) of patients with recurrent tumor presented with triple negative results. There were significant association between breast cancer subtypes at time of recurrence and grade of disease, type of surgery, histopathological diagnosis, type of treatment including chemotherapy, hormonal therapy and monoclonal antibodies inwhich the p value were 0.002, 0.044, 0.011, 0.015, 0.001 and 0.002 respectively.


Relapsed breast cancer should include confirmatory tissue sampling and the molecular subtypes of breast cancer were changed significantly from luminal A and B domination in the primary breast cancer to Triple negative domination in the relapsed cancer which mandate the change of therapeutic management of patients.



Recurrent breast cancer, Biopsy, Luminal A and B, Triple-Prognosis.


║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
597,088,126 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.